Biogen Pharmachem Q1 Results: Net profit rises to ₹22.14 lakh, revenue up YoY
Biogen Pharmachem Industries returned to profitability in Q1FY26 with a net profit of ₹22.14 lakh, reversing a loss in the prior quarter. Revenue stood at ₹44.34 lakh, driven by other operating income, while expenses dropped significantly. Statutory auditors Goenka Mehta And Associates reviewed the results.
*this image is generated using AI for illustrative purposes only.
Biogen Pharmachem Industries Limited reported a net profit of ₹22.14 lakh for the quarter ended June 30, 2026, marking a return to profitability after posting a net loss of ₹35.88 lakh in the preceding quarter. The company’s revenue from operations rose to ₹44.34 lakh in Q1FY26, up from ₹154.28 lakh in the same quarter last year, while total expenses declined significantly to ₹22.20 lakh from ₹93.70 lakh in Q4FY26. This turnaround highlights improved operational efficiency and cost management during the period.
The Board of Directors approved the unaudited standalone financial results during a meeting held on August 05, 2026, at the company’s registered office in Rajkot. The results were reviewed by the Audit Committee and subjected to a limited review by the statutory auditors, Goenka Mehta And Associates, in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Financial Performance Overview
The company’s financial performance in Q1FY26 showed distinct improvements across key metrics compared to both the immediate prior quarter and the corresponding period in the previous fiscal year.
| Particulars | Q1FY26 (₹ Lakh) | Q4FY26 (₹ Lakh) | Q1FY25 (₹ Lakh) |
|---|---|---|---|
| Revenue from Operations | 44.34 | 57.82 | 154.28 |
| Total Expenses | 22.20 | 93.70 | 19.80 |
| Profit Before Tax | 22.14 | (35.88) | 134.48 |
| Net Profit After Tax | 22.14 | (35.88) | 134.48 |
Revenue from operations was entirely derived from other operating revenue, amounting to ₹44.34 lakh. There were no gross revenues from the sale of products reported for the quarter. Employee benefit expenses decreased sharply to ₹2.28 lakh from ₹10.31 lakh in the previous quarter, contributing to the reduction in total expenses. Other expenses also fell to ₹19.92 lakh from ₹83.39 lakh in Q4FY26.
What the Numbers Show
A notable aspect of the quarter’s performance is the divergence between revenue trends and expense management. While revenue from operations declined year-on-year from ₹154.28 lakh to ₹44.34 lakh, the company managed to turn profitable by drastically cutting costs. The absence of finance costs and depreciation expenses in the current quarter further aided the bottom line. Additionally, paid-up equity share capital increased to ₹10,530.37 lakh from ₹9,026.03 lakh in the previous quarter, indicating potential capital infusion or share issuance activity during the period. Earnings per share remained flat at ₹0.00 due to the large base of equity shares relative to the profit magnitude.
Historical Stock Returns for Biogen Pharmachem
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.70% | +3.70% | -12.50% | -52.54% | -63.64% | -56.92% |
What strategic initiatives is Biogen Pharmachem pursuing to restore product-based revenue, given that Q1FY26 earnings were derived entirely from other operating revenue?
How will the recent increase in paid-up equity share capital impact future dilution for existing shareholders or fund upcoming operational expansions?
Can the significant reduction in employee benefit and other expenses be sustained in subsequent quarters without compromising long-term operational capacity?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
